GSK to Transfer Gene Therapy Portfolio to Orchard Therapeutics – Rare Disease Report
Rare Disease Report |
GSK to Transfer Gene Therapy Portfolio to Orchard Therapeutics
Rare Disease Report Mathew Shanley. On Thursday, GlaxoSmithKline (GSK) announced that it will be transferring its portfolio of approved and investigational gene therapies to Orchard Therapeutics in exchange for a 19.9% stake in the company. Under the agreed terms, GSK … Glaxo to Sell Rare Disease Gene Therapies to Private Biotech Orchard Therapeutics to buy GSK's rare disease gene therapy portfolio Strategic agreement to strengthen rare disease gene therapy portfolio |
